Visual outcomes of phakic intraocular lens toric Artiflex

Session Details

Session Title: Keratoconus and Phakic IOLs

Session Date/Time: Monday 12/09/2016 | 16:30-18:30

Paper Time: 17:51

Venue: Hall C4

First Author: : S.Monteiro PORTUGAL

Co Author(s): :    I. Casal   M. Lume   R. Salgado   M. Brochado           

Abstract Details

Purpose:

To evaluate the efficacy, stability and safety of the foldable anterior chamber iris supported phakic Intraocular lens (IOL) Toric Artiflex® (Ophtec) for the correction of myopia with astigmatism.

Setting:

Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal

Methods:

One hundred twenty-eight eyes of 89 patients with moderate to high myopia (-0.50 and -13.50 Diopters (D)) and astigmatism (-0.75 to -5.25 D) were implanted with Toric Artiflex®. Mean implanted spherical and cylindrical powers were -1.00 ± -13.00 D and -1.00 ± -5.00 D, respectively. Follow-up period ranged from 6 to 30 months. Outcome measures were uncorrected visual acuity (UCVA), best spectacle corrected visual acuity (BSCVA), refraction and intraocular pressure. Morphometric evaluation (with Orbscan II® and Pentacam HR®), and endothelial cell density (with specular microscopy ICONAN®) were also assessed.

Results:

All eyes achieved post-operative refractions within +/- 1.00 D (spherical equivalent) of the intended refraction, with astigmatism ranging from 0.00 to 0.75 D. No eyes experienced loss of BSCVA. Post-operative UCVA was 20/25 or superior in every case except two eyes with amblyopia that achieved 20/30. There was no significant decrease in endothelial cell density at the end of follow-up. There was one case of traumatic haptic subluxation which was successfully resolved with a second surgical procedure and few cases of pigment precipitates. No major complications (cataract, glaucoma or endophthalmitis) occurred. Patient satisfaction was very high.

Conclusions:

The Artiflex® Toric phakic IOL revealed a stable and predictable visual results in the correction of moderate to high myopia and astigmatism, with no major safety-concerned complications and good satisfaction.

Financial Disclosure:

NONE